EGFR and neoplasm: Therefore, it is crucial to highlight that the current approval of osimertinib is restricted to the adjuvant therapy after complete tumor resection in adult patients with stage IB-IIIA non-squamous cell lung carcinoma harboring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations [24,25].